These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33072871)

  • 1. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest.
    Hartman WR; Hess AS; Connor JP
    Transl Med Commun; 2020; 5(1):17. PubMed ID: 33072871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest.
    Hartman W; Hess AS; Connor JP
    medRxiv; 2020 Jun; ():. PubMed ID: 32607514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalized COVID-19 Patients treated with Convalescent Plasma in a Mid-size City in the Midwest.
    Hartman WR; Hess AS; Connor JP
    Res Sq; 2020 Sep; ():. PubMed ID: 32793897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospitalized COVID-19 Patients treated with Convalescent Plasma in a Mid-size City in the Midwest.
    Hartman WR; Hess AS; Connor JP
    Res Sq; 2020 Jul; ():. PubMed ID: 32702731
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience.
    Joyner MJ; Senefeld JW; Klassen SA; Mills JR; Johnson PW; Theel ES; Wiggins CC; Bruno KA; Klompas AM; Lesser ER; Kunze KL; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; van Helmond N; van Buskirk CM; Winters JL; Stubbs JR; Rea RF; Hodge DO; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Buras MR; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Paneth NS; Fairweather D; Wright RS; Carter RE; Casadevall A
    medRxiv; 2020 Aug; ():. PubMed ID: 32817978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial.
    Ibrahim D; Dulipsingh L; Zapatka L; Eadie R; Crowell R; Williams K; Wakefield DB; Cook L; Puff J; Hussain SA
    Infect Dis Ther; 2020 Dec; 9(4):913-926. PubMed ID: 32951151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma.
    Ma T; Wiggins CC; Kornatowski BM; Hailat RS; Clayburn AJ; Guo WL; Johnson PW; Senefeld JW; Klassen SA; Baker SE; Bruno KA; Fairweather D; Wright RS; Carter RE; Li C; Joyner MJ; Paneth NS
    Front Med (Lausanne); 2021; 8():707895. PubMed ID: 35155458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol.
    Faqihi F; Alharthy A; Alodat M; Asad D; Aletreby W; Kutsogiannis DJ; Brindley PG; Karakitsos D
    Trials; 2020 Jun; 21(1):506. PubMed ID: 32513290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma.
    Senefeld JW; Johnson PW; Kunze KL; van Helmond N; Klassen SA; Wiggins CC; Bruno KA; Golafshar MA; Petersen MM; Buras MR; Klompas AM; Sexton MA; Soto JCD; Baker SE; Shepherd JRA; Verdun NC; Marks P; van Buskirk CM; Winters JL; Stubbs JR; Rea RF; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Wright K; Greenshields JT; Paneth NS; Fairweather D; Wright RS; Casadevall A; Carter RE; Joyner MJ
    medRxiv; 2021 Apr; ():. PubMed ID: 33851175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
    Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
    Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated with Convalescent Plasma.
    Ma T; Wiggins CC; Kornatowski BM; Hailat RS; Clayburn AC; Guo W; Johnson PW; Senefeld JW; Klassen SA; Baker SE; Bruno KA; Fairweather D; Wright RS; Carter RE; Li C; Joyner MJ; Paneth N
    medRxiv; 2021 Jan; ():. PubMed ID: 33501470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas.
    Salazar E; Perez KK; Ashraf M; Chen J; Castillo B; Christensen PA; Eubank T; Bernard DW; Eagar TN; Long SW; Subedi S; Olsen RJ; Leveque C; Schwartz MR; Dey M; Chavez-East C; Rogers J; Shehabeldin A; Joseph D; Williams G; Thomas K; Masud F; Talley C; Dlouhy KG; Lopez BV; Hampton C; Lavinder J; Gollihar JD; Maranhao AC; Ippolito GC; Saavedra MO; Cantu CC; Yerramilli P; Pruitt L; Musser JM
    medRxiv; 2020 May; ():. PubMed ID: 32511574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccinated and Convalescent Donor-Derived Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients.
    Papayanni PG; Chasiotis D; Koukoulias K; Georgakopoulou A; Iatrou A; Gavriilaki E; Giannaki C; Bitzani M; Geka E; Tasioudis P; Chloros D; Fylaktou A; Kioumis I; Triantafyllidou M; Dimou-Besikli S; Karavalakis G; Boutou AK; Siotou E; Anagnostopoulos A; Papadopoulou A; Yannaki E
    Clin Infect Dis; 2021 Dec; 73(11):2073-2082. PubMed ID: 33905481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients.
    Joyner M; Wright RS; Fairweather D; Senefeld J; Bruno K; Klassen S; Carter R; Klompas A; Wiggins C; Shepherd JR; Rea R; Whelan E; Clayburn A; Spiegel M; Johnson P; Lesser E; Baker S; Larson K; Ripoll Sanz J; Andersen K; Hodge D; Kunze K; Buras M; Vogt M; Herasevich V; Dennis J; Regimbal R; Bauer P; Blair J; van Buskirk C; Winters J; Stubbs J; Paneth N; Casadevall A
    medRxiv; 2020 May; ():. PubMed ID: 32511566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.
    Thompson MA; Henderson JP; Shah PK; Rubinstein SM; Joyner MJ; Choueiri TK; Flora DB; Griffiths EA; Gulati AP; Hwang C; Koshkin VS; Papadopoulos EB; Robilotti EV; Su CT; Wulff-Burchfield EM; Xie Z; Yu PP; Mishra S; Senefeld JW; Shah DP; Warner JL;
    JAMA Oncol; 2021 Jun; 7(8):1167-75. PubMed ID: 34137799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 63-Year-Old Woman with SARS-CoV-2 Infection, Who Developed Severe COVID-19 Pneumonia and Was Supported with Convalescent Plasma Therapy.
    Moniuszko-Malinowska A; Czupryna P; Boczkowska-Radziwon B; Wasiluk T; Borawski K; Dunaj J; Bujno M; Radziwon P; Rutkowski K; Pancewicz S
    Am J Case Rep; 2020 Sep; 21():e927662. PubMed ID: 32991573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral load evolution and immune response.
    Aldunate F; Fajardo A; Ibañez N; Rammauro F; Daghero H; Arce R; Ferla D; Pereira-Gomez M; Salazar C; Iraola G; Pritsch O; Hurtado J; Tenzi J; Bollati-Fogolín M; Bianchi S; Nin N; Moratorio G; Moreno P
    Front Nephrol; 2023; 3():1132763. PubMed ID: 37675346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients.
    Klapholz M; Pentakota SR; Zertuche JP; McKenna M; Roque W; Forsberg M; Packer J; Lal DS; Dever L
    Open Forum Infect Dis; 2021 Feb; 8(2):ofab001. PubMed ID: 33604400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.